Peter Gelinas

Over 13 years of Cell and Gene therapy experience in manufacturing and CMC product development from candidate nomination to commercialization. At Elevate bio, Pete heads up the Manufacturing and Technical Operations departments overseeing aspects of Technology Transfer, CMC strategy, and oversite of routine clinical manufacturing for the Elevate bio portfolio and strategic partners. Pete has been with Elevate for over three years and helped the facility and system build out.

At bluebird bio he led both the Drug Product MS&T group and CMC team for the Lenti-D Gene Therapy program for the Treatment of Cerebral Adrenoleukodystrophy (CALD) for more than four years. In his MS&T role, he completed multiple late-phase global technology transfers and led the drug product process validation efforts instrumental to filing the Marketing Authorization Application (MAA) for Zynteglo. Peter also held various roles at the Connell O’Reilly Cell Manipulation Core Facility (CMCF) at Dana Farber Cancer Institute (DFCI), assisting in the development and manufacturing of gene and cell-based therapies for conditions such as melanoma, MDS/AML, ALS, SCID-X1, and Wiskott Aldrich Syndrome (WAS).